Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases ( VEGFR1 , VEGFR2 , VEGFR3 , PDGFRα and c-Kit ), mitosis-related kinase Aurora B , and chronic inflammation-related kinase CSF-1R , with IC 50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects.